Oren Livnat
Recent Articles about Verrica Pharmaceuticals Inc.
Strong Early Launch Metrics for Biotech's Skin Disease Drug 11/20/2023
Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.
© 2024 Streetwise Reports. All rights reserved.
Streetwise Reports is registered with the U.S. Patent and Trademark Office.
